Uncommon Mutations at Residue Positions Critical for Enfuvirtide (T-20) Resistance in Enfuvirtide-Naive Patients Infected With Subtype B and Non-B HIV-1 Strains-Reference-Cited by-同舟云学术

Uncommon Mutations at Residue Positions Critical for Enfuvirtide (T-20) Resistance in Enfuvirtide-Naive Patients Infected With Subtype B and Non-B HIV-1 Strains

Published:2003-06 Issue:2 Volume:33 Page:134-139
ISSN:1525-4135
Container-title:JAIDS Journal of Acquired Immune Deficiency Syndromes
language:en
Short-container-title:JAIDS Journal of Acquired Immune Deficiency Syndromes

Author:

Roman François,Gonzalez Dimitri,Lambert Christine,Deroo Sabrina,Fischer Aurélie,Baurith Thérèse,Staub Thérèse,Boulmé Ronan,Arendt Vic,Schneider François,Hemmer Robert,Schmit Jean-Claude

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Infectious Diseases

Reference20 articles.

1. Current Evidence and Future Directions for Targeting HIV Entry

2. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection.

3. HIV Entry and Its Inhibition

4. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry

5. Determinants of Human Immunodeficiency Virus Type 1 Resistance to gp41-Derived Inhibitory Peptides

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Massively Parallel Profiling of HIV-1 Resistance to the Fusion Inhibitor Enfuvirtide;Viruses;2019-05-15

2. Genotypic Assays for Monitoring Drug Resistance in HIV-1 Infection and for Other Chronic Viral Diseases;Antimicrobial Drug Resistance;2017

3. Escape from Human Immunodeficiency Virus Type 1 (HIV-1) Entry Inhibitors;Viruses;2012-12-19

4. Inhibition of HIV-1 by Fusion Inhibitors;Current Pharmaceutical Design;2010-11-01

5. Enfuvirtide: from basic investigations to current clinical use;Expert Opinion on Pharmacotherapy;2010-10-27